
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
"This particular study comes from our human randomized trial that we hope will be the final step before FDA approval for the technology,” says Mathew D. Sorensen, MD, MS, FACS.
In this video, Mathew D. Sorensen, MD, MS, FACS, discusses the background and learning curve of ultrasonic propulsion stone treatment, from the study, “




